Trinity Biotech (NASDAQ: TRIB) regains compliance with Nasdaq listing rules

Rhea-AI Filing Summary

Trinity Biotech plc filed a Form 6-K to report that, as of September 2, 2025, it has regained compliance with Nasdaq Listing Requirements. This means the company once again meets the standards needed for its shares to remain listed on the Nasdaq market. The filing notes that this update was first announced in a press release, which is included as Exhibit 99.1. The document is also incorporated by reference into Trinity Biotech’s existing employee share plan registration statements on Form S-8.

Insights

Equity Markets & Listing Standards Analyst

Trinity Biotech has restored full Nasdaq listing compliance, easing delisting concerns.

Trinity Biotech plc states that it has regained compliance with Nasdaq Listing Requirements as of September 2, 2025. Regaining compliance indicates that earlier listing deficiencies have been resolved to Nasdaq’s satisfaction, which typically removes the immediate risk of forced delisting from the exchange.

This development primarily affects trading status and market accessibility rather than the underlying business results, which are not discussed here. Continued compliance will depend on the company maintaining Nasdaq’s financial, governance, and disclosure standards in future periods.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).

EXPLANATORY NOTE

On September 2, 2025, the Company issued a press release announcing that it had regained compliance with Nasdaq Listing Requirements. A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Regains Compliance with Nasdaq Listing Requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ John Gillard
		John Gillard
		Chief Executive Officer

Date:  September 2, 2025

FAQ

What did Trinity Biotech plc (TRIB) report in this Form 6-K?

Trinity Biotech plc reported that as of September 2, 2025, it had regained compliance with Nasdaq Listing Requirements, as described in a press release attached as Exhibit 99.1.

What does it mean that Trinity Biotech (TRIB) regained Nasdaq compliance?

Regaining Nasdaq compliance means Trinity Biotech plc once again meets the exchange’s required listing standards, which allows its shares to remain listed and traded on the Nasdaq market.

Where can investors find more details on Trinity Biotech’s Nasdaq compliance update?

More details are contained in the company’s press release titled “Trinity Biotech Regains Compliance with Nasdaq Listing Requirements”, which is filed as Exhibit 99.1 to the Form 6-K.

How is this Form 6-K used in relation to Trinity Biotech’s share plans?

The Form 6-K is incorporated by reference into Trinity Biotech’s existing Form S-8 registration statements, which cover securities issued under the company’s employee and incentive plans.

Does this Form 6-K include financial results for Trinity Biotech (TRIB)?

No, this Form 6-K is focused on the company’s Nasdaq listing compliance status and the related press release; it does not present financial results.